CDX2 and cancer: In our study, there was an increase in the percentage of cases with loss of CDX2 expression as the cancer stage advanced, i.e., stages I (3.5%), II (5.0%), III (10.7%) and IV (12.1%), which was statistically significant (p = 0.015).